Tuesday, August 22, 2017 5:11:04 PM
BTX...a gene therapy stem cell company...
I have a 1/3 position now and would like to add more shares on a drawback to $2.50 or lower... a couple of brokerJOKERs have a $6 price target here...
https://finance.yahoo.com/news/biotime-receives-dsmb-approval-start-203000419.html
The Phase I/IIa clinical trial is evaluating the safety and efficacy of implantation regimens of OpRegen in the advanced form of dry-AMD. Dry-AMD is the leading cause of blindness in people over 60, and a condition for which there is currently no FDA-approved therapy. OpRegen has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of dry-AMD, which comprises approximately 90% of those afflicted with AMD.
Daily
60minute
BTX
I have a 1/3 position now and would like to add more shares on a drawback to $2.50 or lower... a couple of brokerJOKERs have a $6 price target here...
https://finance.yahoo.com/news/biotime-receives-dsmb-approval-start-203000419.html
The Phase I/IIa clinical trial is evaluating the safety and efficacy of implantation regimens of OpRegen in the advanced form of dry-AMD. Dry-AMD is the leading cause of blindness in people over 60, and a condition for which there is currently no FDA-approved therapy. OpRegen has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of dry-AMD, which comprises approximately 90% of those afflicted with AMD.
Daily
60minute
BTX
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
